Pharma BD landscape within the molecular glue space With last week's Lilly / Magnet Biomedicine $1.3B deal, we're now up to 24 deals led by big pharma since 2020, totaling ~$27B in total disclosed deal values What's causing all of these companies to jump in? Some thoughts:

The oncology dealmaking landscape is shifting! Pharma is moving beyond niche drugs to focus on ADCs, bispecifics & radioligand therapies. Low interest in narrow biomarker drugs, pharma is chasing pan-cancer blockbusters! #OncologyDeals #Pharma nature.com/articles/d4374…

面白そうなオンラインイベントだな、と思ったけどRCS非会員だと15,000円くらいか。うーん。 BMCS Hot Topics: PROTACs and Glues 2025 rscbmcs.org/events/hottopi…

PD-(L)1 x VEGF global competitive landscape An exhaustive list of programs surfaced by Sleuth from patents, company websites, news / press releases, conference abstracts and publications. Plus some thoughts on how this opportunity will evolve in 2025 and beyond: While

From Cantor: Biotech – is the sector broken, or is it just a bear market? or is it both?

Pfizer's ex CSO & president of global research & development Mikael Dolsten announced he's working w/ AI-native pharma Formation Bio as an advisor & he'll be leading their drug-picking committee. More below incl Endpoints News story

cGAMP production by cancer cells promotes anti-tumor immunity. A new study highlights the good and bad of cGAMP in the TME, with significant implications for clinical use of STING agonists. cell.com/cell-reports/f…

The IRA triggered a 74% drop in investment for pills treating Medicare patients. Alzheimer's, cancer, and other therapies are now at risk. Equal timelines could help restore progress. 📄buff.ly/Agz6GuJ We Work For Health #IRA #DrugPricing #Pharma #PIllPenalty #Research

TL1A global competitive landscape An exhaustive list of programs surfaced by Sleuth from patents, company websites, news / press releases, conference abstracts and publications. Plus some thoughts on this opportunity will evolve in 2025 and beyond: This is a hot

(K)RAS data updates expected at AACR (From Jefferies)

The IRA was meant to help seniors, but it’s decreasing early investment in treatments for age-related diseases. Small molecule therapies for conditions affecting largely Medicare patients saw a 74% drop in median investment. More from We Work For Health: buff.ly/pJIyINT

An exciting new drug for #PBC pruritus on the horizon 🌅

Excellent report from Cowen on urticaria, a commercially significant and untapped I&I indication. cKIT seems to be the most promising target, $CLDX expected to report P3 in 2026.

There's no free lunch in biotech. When you take less scientific risk by pursuing a more validated MoA, you're taking much more market risk from the increased competition. You're always trading off one type of risk for another.

Great overview of the major licensing deals in Chinese biotech that happened since 2022 🇨🇳🇪🇺🇺🇸🔥💸 $XBI

Interesting analysis on top I&I targets and the change from 2020 to 2024. This doesn't include a huge wave of bispecific and half life extended monospecfic programs that are still in P1 or preclin stage. Surprising to see so much activity with JAKs and TYK2 given issues with

1/ 🧬 How to Price a Platform in Biotech Q2 M&A is ripping, Capstan just cleared $2.1B at Phase 1, and something important has changed. A new market dynamic may be emerging, where optionality matters again. Let’s break it down with math, comps, and a framework 🧵

One potent gene raises risk of Alzheimer’s, Parkinson’s and other brain diseases nature.com/articles/d4158…

Broad et al. find that the TRPA1 antagonist LY3526318 inhibited behavioral signs of enhanced nociception in animal models and was safe and well tolerated in phase 1 clinical studies. Learn more in #PAIN bit.ly/4kNYFZF

Get in touch to uncover white space opportunities and BD strategies for your pipeline programs